Alpha-1-antitrypsin-deficiency is associated with lower cardiovascular risk: an approach based on federated learning

Table 4 Mean differences of laboratory parameters in all COPD patients. The confounders for the adjusted mean differences include age, gender and nicotine abuse. Unadjusted mean differences for AATD vs. Non-AATD COPD patients in laboratory parameters

Laboratory parameter	⁺Mean difference	Lower CI	Upper CI	p-value	Unit
a) Unadjusted mean differences for AATD vs. Non-AATD COPD patients in laboratory parameters
ALAT	20.16	3.26	36.18	0.019	U/L
ASAT	52.91	9.74	95.91	0.016	U/L
Blood glucose	99.96	-818.6	1001.7	0.844	mg/dL
HbA1c	-0.61	-0.96	-0.35	0.001	mmol/mol
HDL	-2.33	-5.07	1.44	0.275	mg/dL
LDL	-4.28	-11.94	2.19	0.177	mg/dL
Triglyceride*	-2.7	-23.18	6.03	0.250	mg/dL
Total Cholesterol	-7.72	-17.55	-1.59	0.019	mg/dL
b) Adjusted mean differences for AATD vs. Non-AATD COPD patients in laboratory parameters
ASAT	38.05	13.26	62.82	0.002	U/L
ALAT	11.77	1.49	22.05	0.024	U/L
Blood glucose	7.55	0.07	51,500,000	0.147	mg/dL
HbA1c	-0.52	-0.80	-0.23	0.001	mmol/mol
HDL	-2.24	-5.11	0.62	0.125	mg/dL
LDL	-5.03	-15.44	5.37	0.343	mg/dL
Triglyceride*	-10.57	n.a	n.a	0.205	mg/dL
Total Cholesterol	-11.04	-19.19	-2.88	0.007	mg/dL

⁺ The mean difference for AATD (n = 55) is relative to Non-AATD (n = 4365) and the p-value is that of the student’s t-test comparison. CI: Confidence Interval, U/L: Units per litre, mg/dl: Milligrams per decilitre, mmol/mol: Millimoles per mole, AATD: Alpha 1-Antitrypsin Deficiency, ASAT: Aspartate Aminotransferase, ALAT: Alanine Aminotransferase, HbA1c: Glycosylated haemoglobin, HDL: High Density Lipoprotein, LDL: Low Density Lipoprotein
^∗The difference here includes all sites except Site F cohort (n.a is due to DataSHIELD disclosure controls)

ISSN: 1465-993X